Item 5.07. Submission of Matters to a Vote of Security Holders.





On June 29, 2021, Therapeutics Acquistion Corp., d/b/a Research Alliance Corp.
I, a Delaware corporation ("RACA" or the "Company"), held a special meeting of
stockholders (the "Special Meeting"). At the Special Meeting, a total of
12,540,080 (71.92%) of RACA's issued and outstanding shares of common stock held
of record as of June 4, 2021, the record date for the Special Meeting, were
present either in person or by proxy, which constituted a quorum. RACA's
stockholders voted on the following proposals at the Special Meeting, each of
which was approved. The final vote tabulation for each proposal is set forth
below.



    1.  The Business Combination Proposal. To adopt a proposal to (a) adopt and
        approve the Business Combination Agreement, dated as of March 15, 2021,
        (as may be amended, supplemented or otherwise modified from time to time,
        the "Business Combination Agreement"), by and among RACA, Bodhi Merger
        Sub, Inc., a Delaware corporation ("Merger Sub"), a wholly-owned
        subsidiary of RACA, and POINT Biopharma Inc., a Delaware corporation
        ("POINT"), pursuant to which Merger Sub will merge with and into POINT,
        with POINT surviving the merger as a wholly-owned subsidiary of RACA and
        (b) approve the Business Combination Combination (as defined in the
        Business Combination Agreement). In connection with the Business, RACA
        will be renamed "POINT Biopharma Global Inc.," ("New POINT") and POINT
        will retain its name "POINT Biopharma Inc." Subject to the terms and
        conditions set forth in the Business Combination Agreement, at the
        Effective Time (as defined in the Business Combination Agreement):




     (i)  each share and vested equity award of POINT outstanding as of
          immediately prior to the Effective Time will be exchanged for shares of
          New POINT Common Stock or comparable vested equity awards that are
          exercisable for shares of New POINT Common Stock, based on an implied
          POINT vested equity value of $585,000,000;

     (ii) all unvested equity awards of POINT will be exchanged for comparable
          equity awards that are exercisable for shares of New POINT Common Stock,
          determined based on the same exchange ratio at which the vested equity
          awards are exchanged for shares of New POINT Common Stock; and




     (iii) each share of Class A Common Stock and each share of Class B Common
           Stock that is issued and outstanding immediately prior to the Effective
           Time shall become one share of New POINT Common Stock:




Votes For      Votes Against     Abstentions
12,486,339        52,265            1,476




    2.  The Charter Amendment Proposal. To adopt a proposal to approve, assuming
        the Business Combination Proposal is approved and adopted, a proposed
        amended and restated certificate of incorporation (the "Proposed
        Charter"), which will amend and restate RACA's current second amended and
        restated certificate of incorporation (the "Current Charter"), and which
        Proposed Charter will be in effect when duly filed with the Secretary of
        the State of the State of Delaware in connection with the Closing (as
        defined in the Business Combination Agreement):




Votes For      Votes Against     Abstentions
12,486,339        52,446            1,302

The Advisory Charter Proposals. To adopt a proposal to approve, on a non-binding advisory basis, the following material differences between the Proposed Charter and the Current Charter, which are being presented in accordance with the requirements of the Securities and Exchange Commission as seven separate sub-proposals:





    3.  Advisory Charter Proposal A - To change the corporate name of New POINT to
        "POINT Biopharma Global Inc:




Votes For      Votes Against     Abstentions
12,486,513        52,265            1,302










    4.  Advisory Charter Proposal B - To increase the RACA's capitalization so
        that it will have 430,000,00 authorized shares of common stock and
        20,000,000 authorized shares of preferred stock:




Votes For      Votes Against     Abstentions
12,067,405        58,566           414,109




    5.  Advisory Charter Proposal C - To provide that the removal of any director
        be only for cause and by the affirmative vote of at least 66 2/3% of New
        POINT's then-outstanding shares of capital stock entitled to vote
        generally in the election of directors:




Votes For      Votes Against     Abstentions
10,984,034       1,548,770          7,276




    6.  Advisory Charter Proposal D - To provide that certain amendments to
        provisions of the Proposed Charter will require the approval of at least
        66 2/3% of New POINT's then-outstanding shares of capital stock entitled
        to vote on such amendment:




Votes For      Votes Against     Abstentions
10,985,684       1,548,770          5,851




    7.  Advisory Charter Proposal E - To make New POINT's corporate existence
        perpetual as opposed to the RACA's corporate existence, which is required
        to be dissolved and liquidated 24 months following the closing of its
        initial public offering, and remove from the Proposed Charter the various
        provisions applicable only to special purpose acquisition companies:




Votes For      Votes Against     Abstentions
12,074,955        52,266           412,489




    8.  Advisory Charter Proposal F - To provide that New POINT will not be
        subject to Section 203 of the DGCL, which prohibits Delaware corporations
        from entering into business combinations with interested stockholders,
        defined as those that hold more than 15% or more of the corporation's
        voting stock, absent the receipt of specific approvals specified in
        Section 203 of the DGCL:




Votes For     Votes Against     Abstentions
12,486,53        52,266            1,301




    9.  Advisory Charter Proposal G - To remove the provisions setting the Court
        of Chancery of the State of Delaware as the sole and exclusive forum for
        certain stockholder actions:




Votes For     Votes Against     Abstentions
12,480,00        54,229            5,851




    10. The Nasdaq Stock Issuance Proposal. To adopt a proposal to approve,
        assuming the Business Combination Proposal is approved and adopted,
        (a) the issuance of up to 60,240,279 newly issued shares of New POINT
        Common Stock in the Business Combination, which amount will be determined
        as described in the proxy statement/prospectus for the Special Meeting,
        and (b) the PIPE Investment (as defined in the Business Combination
        Agreement):




Votes For      Votes Against     Abstentions
12,067,502        58,294           414,284




    11. The Director Election Proposal. To approve, assuming the Business
        Combination Proposal is approved and adopted, the appointment of nine
        directors who, upon consummation of the Business Combination, will become
        directors of New POINT:




Votes For      Votes Against     Abstentions
12,537,153          376             2,551










    12. The Equity Incentive Plan Proposal. To adopt a proposal to approve,
        assuming the Business Combination Proposal is approved and adopted, the
        2021 Equity Incentive Plan (the "Equity Incentive Plan"), a copy of which
        is appended to the Business Combination Agreement as Exhibit G, which will
        become effective the day prior to the Closing:




Votes For      Votes Against     Abstentions
12,479,010        53,794            7,276


Item 8.01 Other Events.

In connection with the Business Combination, holders of 1,394,131 shares of RACA's common stock exercised their right to redeem their shares, a per share price of approximately $10.00, for aggregate consideration of $13,941,310.00.

© Edgar Online, source Glimpses